Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyrotinib, Trastuzumab, and Taxanes in HER2+ Advanced Breast Cancer
NCT06217185Phase 4Recruiting
- Sponsor
- The Fourth Hospital of Hebei Medical University
- Start
- Jan 2024
- Primary completion
- Dec 2025
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 4 trial of pyrotinib in breast cancer, sponsored by The Fourth Hospital of Hebei Medical University. Started Jan 2024; status: recruiting.
02
Drugs
pyrotinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06217185.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06217185.